The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Photoallergic Contact Dermatitis

A type IV delayed-hypersensitivity reaction triggered by UVA exposure activating a photoallergen on the skin; presents as eczematous dermatitis confined to sun-exposed areas, classically caused by topical sunscreens (oxybenzone), NSAIDs (ketoprofen), and antibiotics; diagnosis by photopatch testing.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Photoallergic Contact Dermatitis?

Photoallergic contact dermatitis (PACD) is a delayed-type (type IV) hypersensitivity reaction in which a substance applied to the skin (or rarely systemic) becomes immunogenic only after absorbing ultraviolet A (UVA) radiation. The photoallergen undergoes UV-induced photochemical transformation (often via free radical generation or covalent binding to skin proteins), creating a hapten-protein complex that is processed by Langerhans cells, presented to sensitized T cells, and triggers a delayed inflammatory response 24–72 hours after exposure.

Pathogenesis differs from phototoxic contact dermatitis (which is non-immune, dose-dependent, occurs on first exposure, presents within hours like exaggerated sunburn — e.g., furocoumarins from limes causing phytophotodermatitis or 'margarita dermatitis'). PACD requires prior sensitization (latent period of weeks to months) and recurs on re-exposure to even tiny amounts of allergen plus UVA.

Common photoallergens (vary by region and era): topical sunscreens (oxybenzone, dioxybenzone, sulisobenzone, avobenzone, octocrylene, ecamsule), topical NSAIDs (ketoprofen — leading cause in Europe, 50–70 percent of PACD; etofenamate, piroxicam, diclofenac, ibuprofen), antimicrobials (fenticlor, bithionol, chlorhexidine, triclosan), fragrances (musk ambrette, 6-methylcoumarin, sandalwood), plant compounds (Compositae, Frullania), promethazine, chlorpromazine, quinolones (some), and historical agents (halogenated salicylanilides, hexachlorophene). Diagnosis: clinical pattern (sun-exposed distribution with sparing of shaded areas — submental, retroauricular, eyelids, behind earlobe), photopatch testing (gold standard — duplicate patches, one set irradiated with 5 J/cm² UVA after 24 hours, read at 48 and 96 hours).

Symptoms

Pruritic eczematous papules, vesicles, and plaques on sun-exposed skin
Distribution on face, neck, V of chest, dorsa of hands and forearms
Sparing of shaded areas: upper eyelids, submental area, retroauricular, behind earlobe, scalp under hair
Onset 24–72 hours after sun exposure (delayed)
Recurrence with re-exposure to allergen plus sun
Hand-mediated transfer pattern (e.g., facial dermatitis from applying topical NSAID to back, then touching face)
May develop chronic actinic dermatitis if allergen continues
Often associated with sunscreen, topical NSAID, or fragrance use history

Risk Factors

Topical sunscreen use (oxybenzone, octocrylene — particularly common in patients with photodermatoses already using sunscreens)
Topical NSAID application (ketoprofen — leading cause in Europe; topical diclofenac, piroxicam, etofenamate)
Outdoor occupations and recreations with high sun exposure
Pre-existing photodermatosis (PMLE, chronic actinic dermatitis) — increased sensitization to sunscreens
Fair skin types (Fitzpatrick I-III)
Concomitant atopic dermatitis (impaired barrier increases percutaneous absorption)
Female sex (more sunscreen, fragrance, cosmetic use)
Application of allergen to multiple sites then sun exposure

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Eczematous rash limited to sun-exposed skin
  • Recurrent itchy rash after outdoor activities
  • Suspected reaction to sunscreen, topical pain reliever, or cosmetic
  • Persistent dermatitis despite stopping suspected products — referral for photopatch testing
  • Worsening or chronic actinic dermatitis
  • Difficulty distinguishing from polymorphous light eruption or chronic actinic dermatitis
  • Photodermatitis impacting work or quality of life

Treatment Methods

01
Diagnostic: detailed history (products used, sun exposure pattern, time course, occupation), physical exam (sun-exposed distribution with shaded sparing), photopatch testing (duplicate sets of suspected allergens — sunscreen series, ketoprofen and other NSAIDs, fragrances; one set irradiated with UVA 5 J/cm² 24 hours after application, both sets read at 24, 48, 96 hours; positive only on irradiated side = photoallergic; positive on both = allergic contact dermatitis)
02
Identify and strictly avoid the photoallergen and any cross-reacting substances (e.g., ketoprofen cross-reacts with fenofibrate, oxybenzone with benzophenones in fragrances and plastics)
03
Provide written list of all known allergens and cross-reactors; check labels of all personal care products
04
Switch to physical-only sunscreens (zinc oxide, titanium dioxide) if oxybenzone/octocrylene allergic; switch to chemical filters if zinc-allergic
05
Strict photoprotection: broad-spectrum sunscreen (UVA + UVB SPF 50+), wide-brim hat, UPF clothing, sun-avoidance during peak hours (10 AM – 4 PM), UV-blocking window film for cars and homes
06
Acute treatment: high-potency topical corticosteroids (clobetasol propionate, betamethasone dipropionate) for 1–2 weeks; topical calcineurin inhibitors (tacrolimus, pimecrolimus) for face and intertriginous areas; emollients
07
Severe or extensive disease: short course of oral prednisone (0.5–1 mg/kg/day taper over 1–3 weeks), systemic antihistamines for pruritus
08
Refractory chronic photoallergic dermatitis or evolution to chronic actinic dermatitis: phototherapy desensitization (PUVA, narrowband UVB), azathioprine, cyclosporine, mycophenolate mofetil
09
Patient education: lifelong avoidance of identified photoallergen, awareness of cross-reactors, importance of physical photoprotection, and reassurance that disease usually resolves within weeks of avoidance

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.